Skip to main content
. Author manuscript; available in PMC: 2020 Oct 8.
Published in final edited form as: Vaccine. 2019 Sep 9;37(43):6500–6509. doi: 10.1016/j.vaccine.2019.08.075

Fig. 4.

Fig. 4.

Percent of Subjects Experiencing Solicited Injection Site Symptoms by Treatment Group, Severity, and Day Post-Vaccination, Post Any Dose. NOTE: A linear mixed effects model estimated the mean duration of injection site symptoms for a person receiving vaccine with GLA-AF to be 1.33 days longer than that of one receiving placebo (p < 0.001) and 1.22 days longer than one who received vaccine alone (p < 0.001).